Working… Menu

Safety and Efficacy Study of Famitinib in Patients With Advanced Colorectal Adenocarcinoma(FACT) (FACT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02390947
Recruitment Status : Completed
First Posted : March 18, 2015
Last Update Posted : December 22, 2020
Information provided by (Responsible Party):
Jiangsu HengRui Medicine Co., Ltd.

Brief Summary:

Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3, whose anti-tumor and anti-angiogenesis effects have been validated in preclinical tests. In PhaseⅡb study, a significantly improved Progression Free Survival (PFS) was found in patients with advanced colorectal cancer treated with Famitinib compared to placebo. On the other hand, the toxicity of Famitinib was manageable in both PhaseⅠand Ⅱb studies.

The purpose of this study is to determine whether Famitinib can improve Overall Survival (OS) compared with placebo in total 540 patients with advanced colorectal cancer who have failed in previously received at least two lines of standard chemotherapy.

Condition or disease Intervention/treatment Phase
Colorectal Cancer Metastatic Colorectal Cancer Recurrent Drug: Famitinib Drug: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 543 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter,Randomized, Double-blind, Placebo-controlled Trial of Famitinib in Patients With Advanced Colorectal Adenocarcinoma
Actual Study Start Date : January 2015
Actual Primary Completion Date : February 2019
Actual Study Completion Date : July 2019

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Famitinib arms
Famitinib 25 mg p.o. qd and the medication continued until disease progression or intolerable toxicity or patients withdrawal of consent
Drug: Famitinib
25 mg p.o. qd

Placebo Comparator: Control arms
Placebo 25 mg p.o. qd and the medication continued until disease progression or intolerable toxicity or patients withdrawal of consent
Drug: Placebo
25 mg p.o. qd

Primary Outcome Measures :
  1. Overall Survival(OS) [ Time Frame: 3 years ]

Secondary Outcome Measures :
  1. Progression Free Survival(PFS) [ Time Frame: 1.5 years ]
  2. Objective response rate(ORR) [ Time Frame: 6 months ]
  3. Disease Control Rate(DCR) [ Time Frame: 1.5 years ]
  4. Quality of Life as measured by EORTC QLQ-C30(3.0) [ Time Frame: 1.5 years ]
  5. The incidence of Adverse Events [ Time Frame: 3 years ]
  6. The severity of Adverse Events [ Time Frame: 3 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female patients aged 18 to 75 (including 18 and 75) at the time of Informed Consent
  2. Pathologically confirmed advanced colorectal adenocarcinoma (all the other histological types are excluded)
  3. Treatment failure in previously received standard therapy (at least two lines), which must include 5-Fu, irinotecan and oxaliplatin

    Definition of "treatment failure":

    A.Disease progression during experimental drug treatment or within 3 months after the last treatment, with definite imaging or clinical evidences;

    B.For patients abandoning chemotherapy because of intolerance of advent events, hematologic toxicity is required to reach ≥Grade IV (platelet decrease ≥ Grade III ), and nonhematologic toxicity is required to reach ≥Grade III , according to NCI CTCAE 4.0. Furthermore, the original treatment should be not tolerated any more when it is repeated to the same patient, judged by investigators.


    A.When adjuvant therapy including oxaliplatin was previously used, at least 9 courses of FOLFOX (2 weeks regimens), 6 courses of CapeOX (3 week regimen), or 750mg/m^2 cumulative consumption of oxaliplatin, are required. Adjuvant therapy will be regarded as the first-line treatment when disease progressed during or within 6 months after treatments

    B.Monoclonal antibody drugs (bevacizumab, cetuximab, panitumumab, aflibercept, etc.) are allowed to combine with prior chemotherapy.

  4. At least one measurable targeting lesion according to RECIST 1.1 (The diameter of tumor and lymph node lesion should be ≥ 10 mm and 15mm, respectively, with scanning layer ≤ 5 mm and without local treatment)
  5. Eastern Cooperative Oncology Group (ECOG) performance status:0-1.
  6. Life expectancy ≥ 3 months
  7. Adequate function of major organs, meaning the following criteria should be met within 14 days before randomization:

    A.Routine blood test:

    1. Hemoglobin > 90g/L (not received blood transfusion or drugs to incraese RBC, Hb, WBC and PLT in 14 days before screening )
    2. Neutrophils > 1.5×10^9/L
    3. Platelets > 100×10^9/L

      B. Blood biochemistry:

    4. Total bilirubin < 1.25×the upper limit of normal (ULN)
    5. Serum transaminase ≤ 2×ULN (≤ 5×ULN, If existing liver metastases)
    6. Creatinine clearance rate ≥ 60ml/min (Cockcroft-Gault Formula)

    C.Doppler echocardiography assessment: Left ventricular ejection fraction (LVEF) ≥ 50%

  8. Having recovered from impairments of other therapy before taking research drugs (more than 6 weeks from the last treatment of Nitroso or MMC, more than 4 weeks from the last treatment of other cytotoxic drugs, targeted drugs, radiotherapy or operation, with completely healed wound, more than 2 weeks from the last treatment of Chinese traditional and patent medicine)
  9. Signed and dated informed consent
  10. Good compliance of patients and agreement of their family members to cooperate on the follow-up of survival.

Exclusion Criteria:

  1. Second malignancies, except for cured skin basal cell carcinoma and carcinoma in-situ of uterine cervix, before or during screening
  2. Previously received therapy of tyrosine kinase inhibitor agent targeting at VEGFR, e.g. famitinib, sorafenib, sunitinib, regorafenib
  3. Having joined in other clinical trials within 4 weeks
  4. Factors influencing the usage of oral administration (e.g. unable to swallow, chronic diarrhea and intestinal obstruction, etc.)
  5. Having haemorrhage history, ≥ Grade Ⅲ (NCI CTCAE 4.0 ) haemorrhage occurred within 4 weeks before screening
  6. Known central nervous system (CNS) metastasis or having CNS metastasis history before screening. CT or MRI scan should be received 28 days before randomization when CNS metastases is clinically suspected
  7. Uncontrolled hypertension with single medical therapy (systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg), History of unstable angina pectoris or newly diagnosed unstable angina pectoris within 3 months before screening, myocardial infarction events within 6 months before screening, Arrhythmias (QTcF: ≥450ms in male, ≥ 470ms in female) needed long-term treatment of drugs, ≥ class II cardiac insufficiency by New York Heart Association (NYHA) classification
  8. urinary protein ≥ ++ or 24-hour urinary protein ≥ 1.0 g
  9. Chronic untreated wounds or fractures
  10. Tumor invasion around major vessels shown by imaging, high risk of major vascular invasion leading to massive hemorrhage judged by investigators
  11. Abnormal international normalized ratio (INR) of patients with coagulation dysfunction and hemorrhagic tendency at 14 days before randomization. Application of anticoagulants or vitamin K antagonists such as warfarin, heparin or its analogues. However, low doses of warfarin (1mg orally, once daily) or aspirin (between 80mg to 100mg daily) can be used for prevention on the premise of INR ≤ 1.5
  12. Artery/venous thromboembolic events occurred within 1 year before screening, such as cerebral vascular accident (including transient ischemic attack), deep vein thrombosis (except for recovered venous thrombosis judged by investigators, which was caused by venous catheter in previous chemotherapy) and pulmonary embolism, etc.
  13. All female patients who are not surgically sterilized or postmenopausal refusing to take a reliable method of birth control during the study and within 6 months after the last dose of test article. All female patients in breastfeeding period or in child-bearing period with a positive urine or serum pregnancy test result before randomization. All male subjects who are not surgically sterilized refusing to take a reliable method of birth control during the study and within 6 months after the last dose of test article.
  14. Preexisted thyroid dysfunction, thyroid function cannot be controlled within normal range even using medical therapy
  15. History of psychiatric drug abuse and addiction, dysphrenia
  16. Symptomatic pleural effusion, hydropericardium or ascites needed clinical intervention or being stable less than 4 weeks.
  17. History of Immunodeficiency, acquired or congenital immunodeficiency, history of organ transplantation
  18. Known active HBV or HCV infection companion with hepatic dysfunction
  19. Concomitant disease judged by investigators that may bring serious harm to the safety of patients or the completion of this study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02390947

Show Show 44 study locations
Sponsors and Collaborators
Jiangsu HengRui Medicine Co., Ltd.
Layout table for investigator information
Principal Investigator: Lin Shen, M.D Beijing Cancer Hospital, Peking University
Principal Investigator: Ruihua Xu, M.D Cancer Center, Sun Yet-sen University
Layout table for additonal information
Responsible Party: Jiangsu HengRui Medicine Co., Ltd. Identifier: NCT02390947    
Other Study ID Numbers: HR-FMTN-CRC-FACT
First Posted: March 18, 2015    Key Record Dates
Last Update Posted: December 22, 2020
Last Verified: May 2017
Keywords provided by Jiangsu HengRui Medicine Co., Ltd.:
Colorectal Cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type